REINALD REVILLA: Open Payments
NPI 1821507716 · TORRANCE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,049 in 35 payments from 9 companies in 2025. Trend: 2023 $164 · 2024 $526 · 2025 $1,049
Food & beverage: $1,049
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 9 | $258 |
| Janssen Pharmaceuticals, Inc | 4 | $235 |
| ABBVIE INC. | 8 | $176 |
| E.R. Squibb & Sons, L.L.C. | 3 | $146 |
| Neos Therapeutics, LP | 4 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Supernus Pharmaceuticals, Inc. | 1 | $26 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
Products named: REXULTI, INVEGA SUSTENNA, VRAYLAR, COBENFY, Adzenys XR-ODT, CAPLYTA, TRINTELLIX, SPRAVATO.
Industry payments across CA — which companies pay providers there.
